Biological evaluation of novel substituted chloroquinolines targeting mycobacterial ATP synthase

International Journal of Antimicrobial Agents

Volumn 41, Issue 1, 2013, Pages 41-46

  Khan, Shaheb Raj ^a   Singh, Supriya ^a   Roy, Kuldeep K ^a   Akhtar, Md Sohail ^a   Saxena, Anil K ^a   Krishnan, Manju Yasoda ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

ATP synthase; Chloroquinolines; Hypoxia; Mycobacterium tuberculosis; Non replicating bacilli

Indexed keywords

2,3 DICHLOROPHENYL; 2,4 DICHLOROPHENYL; 3,5 DIMETHYLPHENYL; 4 CHLOROPHENYL; 4 NITROPHENYL; 5 CHLOROTHIOPHEN 2 YL; ANTIINFECTIVE AGENT; DICYCLOHEXYLCARBODIIMIDE; ISONIAZID; METRONIDAZOLE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; QUINOLONE DERIVATIVE; RIFAMPICIN; THIORIDAZINE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME SPECIFICITY; GROWTH INHIBITION; IC 50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTITUBERCULAR AGENTS; ATP SYNTHETASE COMPLEXES; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; CHLOROQUINOLINOLS; COLONY COUNT, MICROBIAL; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; VERO CELLS;

EID: 84871656535     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.09.012     Document Type: Article

References (24)

1. World Health Organization Global tuberculosis control: WHO report 2011 2011 WHO Geneva, Switzerland
2. C. Dye, S. Scheele, P. Dolin, V. Pathania, and M.C. Raviglione Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project JAMA 282 1999 677 686
3. N.M. Parrish, J.D. Dick, and W.R. Bishai Mechanisms of latency in Mycobacterium tuberculosis Trends Microbiol 6 1998 107 112
4. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva, Switzerland: WHO; 2010. WHO/HTM/TB/2010.3.
5. J.E. Gomez, and J.D. McKinney M. tuberculosis persistence, latency, and drug tolerance Tuberculosis (Edinb) 84 2004 29 44
6. H.M. Vandiviere, W.E. Loring, I. Melvin, and S. Willis The treated pulmonary lesion and its tubercle bacillus, II. The death and resurrection Am J Med Sci 232 1956 30 37
7. L.G. Wayne, and L.G. Hayes An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence Infect Immun 64 1996 2062 2069
8. C.E. Barry, H.I. Boshoff, V. Dartois, T. Dick, S. Ehrt, and J. Flynn The spectrum of latent tuberculosis: rethinking the biology and intervention strategies Nat Rev Microbiol 7 2009 845 855
9. A. Koul, E. Arnoult, N. Lounis, J. Guillemont, and K. Andries The challenge of new drug discovery for tuberculosis Nature 469 2011 483 490
10. A. Koul, L. Vranckx, N. Dendouga, W. Balemans, I. Van den Wyngaert, and K. Vergauwen Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis J Biol Chem 283 2008 25273 25280
11. K. Andries, P. Verhasselt, J. Guillemont, H.W. Göhlmann, J.M. Neefs, and H. Winkler A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 307 2005 223 227
12. L. Shi, C.D. Sohaskey, B.D. Kana, S. Dawes, R.J. North, and V. Mizrahi Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration Proc Natl Acad Sci USA 102 2005 15629 15634
13. S.P. Rao, S. Alonso, L. Rand, T. Dick, and K. Pethe The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis Proc Natl Acad Sci USA 105 2008 11945 11950
14. A. Koul, N. Dendouga, K. Vergauwen, B. Molenberghs, L. Vranckx, and R. Willebrords Diarylquinolines target subunit c of mycobacterial ATP synthase Nat Chem Biol 3 2007 323 324
15. Clinical and Laboratory Standards Institute. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic actinomycetes: approved standard. Document M24-A. Wayne, PA: CLSI; 2003.
16. A.J. Lenaerts, V. Gruppo, K.S. Marietta, C.M. Johnson, D.K. Driscoll, and N.M. Tompkins Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models Antimicrob Agents Chemother 49 2005 2294 2301
17. V.K. Kashyap, R.K. Gupta, R. Shrivastava, B.S. Srivastava, R. Srivastava, and M.K. Parai In vivo activity of thiophene-containing trisubstituted methanes against acute and persistent infection of non-tubercular Mycobacterium fortuitum in a murine infection model J Antimicrob Chemother 67 2012 1188 1197
18. C. Frezza, S. Cipolat, and L. Scorrano Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts Nat Protoc 2 2007 287 295
19. J.J. García, I. Ogilvie, B.H. Robinson, and R.A. Capaldi Structure, functioning, and assembly of the ATP synthase in cells from patients with the T8993G mitochondrial DNA mutation, Comparison with the enzyme in Rho(0) cells completely lacking mtDNA J Biol Chem 275 2000 11075 11081
20. D. Ordway, M. Viveiros, C. Leandro, R. Bettencourt, J. Almeida, and M. Martins Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis Antimicrob Agents Chemother 47 2003 917 922
21. J. van Ingen, T. van der Laan, L. Amaral, R. Dekhuijzen, M.J. Boeree, and D. van Soolingen In vitro activity of thioridazine against mycobacteria Int J Antimicrob Agents 34 2009 190 191
22. C.D. Sohaskey Nitrate enhances the survival of Mycobacterium tuberculosis during inhibition of respiration J Bacteriol 190 2008 2981 2986
23. A.C. Haagsma, N.N. Driessen, M.M. Hahn, H. Lill, and D. Bald ATP synthase in slow- and fast-growing mycobacteria is active in ATP synthesis and blocked in ATP hydrolysis direction FEMS Microbiol Lett 313 2010 68 74
24. E.A. Weinstein, T. Yano, L.S. Li, D. Avarbock, A. Avarbock, and D. Helm Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs Proc Natl Acad Sci USA 102 2005 4548 4553